title: Inhibition of adenylyl cyclase activity by the cholecystokinin analog SNF 9007 in neuroblastoma x glioma NG108-15 hybrid cells.
abstract: The effect of the cholecystokininB (CCKB) receptor-selective cholecystokinin octapeptide (CCK-8) analog SNF 9007 on forskolin-stimulated adenylyl cyclase activity in NG108-15 hybrid cells was measured. The activity of SNF 9007 was compared to the delta opioid agonists D-Pen2-D-Pen5-enkephalin (DPDPE, delta 1 receptor-selective) and Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2, (D-Ala2-deltorphin II, delta 2-receptor-selective) because SNF 9007 binds with moderate affinity to delta opioid receptors. SNF 9007 inhibited forskolin-stimulated adenylyl cyclase activity with efficacy similar to DPDPE. IC50 determinations showed that D-Ala2-deltorphin II was the most potent, followed by DPDPE, then SNF 9007 (IC50 values = 0.013, 0.21 and 4.8 microM, respectively). CCK-8 had no effect on adenylyl cyclase activity. The delta 1 receptor-selective antagonist 7-benzylidenenaltrexone hydrochloride (BNTX, 10 nM) had no effect on the activity of any of these agonists, but the delta 2 receptor-selective antagonist naltriben methanesulfonate (NTB, 10 nM) increased IC50 values of all the agonists. Combinations of BNTX and NTB (10 nM each) increased the D-Ala2-deltorphin II IC50 value 12-fold, the DPDPE IC50 value 18-fold and the SNF 9007 IC50 value 26-fold. The effect of the combined delta antagonists on SNF 9007 activity was different from the effect on DPDPE or D-Ala2-deltorphin II activity. These data suggest that the interaction of the CCK-8 analog SNF 9007 with opioid receptors in NG108-15 hybrid cells is different from the interaction of opioid peptides with these receptors.
authors.affiliation: Department of Pharmacology, Louisiana State University Medical Center, Shreveport 71130, USA.
authors.forename: S C
authors.initials: SC
authors.lastname: Roerig
authors.forename: C L
authors.initials: CL
authors.lastname: Williams
authors.forename: V J
authors.initials: VJ
authors.lastname: Hruby
authors.forename: T F
authors.initials: TF
authors.lastname: Burks
authors.forename: G C
authors.initials: GC
authors.lastname: Rosenfeld
mesh_terms: D000067956:Adenylyl Cyclase Inhibitors; D000595:Amino Acid Sequence; D000700:Analgesics / Q000494:pharmacology*; D002766:Cholecystokinin / Q000031:analogs & derivatives* / Q000494:pharmacology; D020881:Enkephalin, D-Penicillamine (2,5)-; D004745:Enkephalins / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005910:Glioma; D006822:Hybrid Cells / Q000187:drug effects; D008969:Molecular Sequence Data; D009447:Neuroblastoma; D009842:Oligopeptides / Q000494:pharmacology; D010146:Pain / Q000503:physiopathology*; D010446:Peptide Fragments / Q000494:pharmacology*; D017465:Receptors, Opioid, delta / Q000819:agonists
chemical_list: D000067956:Adenylyl Cyclase Inhibitors; D000700:Analgesics; D004745:Enkephalins; D004791:Enzyme Inhibitors; D009842:Oligopeptides; D010446:Peptide Fragments; D017465:Receptors, Opioid, delta; C060209:deltorphin II, Ala(2)-; C085990:SNF 9007; D020881:Enkephalin, D-Penicillamine (2,5)-; D002766:Cholecystokinin